CR20140451A - Anticuerpos dirigidos contra metaloproteinasas de matriz 9 - Google Patents

Anticuerpos dirigidos contra metaloproteinasas de matriz 9

Info

Publication number
CR20140451A
CR20140451A CR20140451A CR20140451A CR20140451A CR 20140451 A CR20140451 A CR 20140451A CR 20140451 A CR20140451 A CR 20140451A CR 20140451 A CR20140451 A CR 20140451A CR 20140451 A CR20140451 A CR 20140451A
Authority
CR
Costa Rica
Prior art keywords
matrix
metaloproteinas
antibodies against
directed antibodies
immunoglobulin
Prior art date
Application number
CR20140451A
Other languages
English (en)
Spanish (es)
Inventor
Joanne I Adamkewicz
Victoria Smith
Zung Thai
Michael J Hawkins
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/027160 external-priority patent/WO2013130078A1/fr
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of CR20140451A publication Critical patent/CR20140451A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR20140451A 2012-02-29 2014-09-25 Anticuerpos dirigidos contra metaloproteinasas de matriz 9 CR20140451A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605181P 2012-02-29 2012-02-29
PCT/US2012/027160 WO2013130078A1 (fr) 2012-02-29 2012-02-29 Anticorps dirigés contre la métalloprotéinase 9 de la matrice
US201361755444P 2013-01-22 2013-01-22
PCT/US2013/028456 WO2013130905A1 (fr) 2012-02-29 2013-02-28 Anticorps dirigés contre la métalloprotéinase 9 de matrice

Publications (1)

Publication Number Publication Date
CR20140451A true CR20140451A (es) 2014-11-17

Family

ID=49003113

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140451A CR20140451A (es) 2012-02-29 2014-09-25 Anticuerpos dirigidos contra metaloproteinasas de matriz 9

Country Status (23)

Country Link
US (2) US9732156B2 (fr)
EP (2) EP2819697A4 (fr)
JP (3) JP6144286B2 (fr)
KR (1) KR20140130513A (fr)
CN (2) CN107184974A (fr)
AP (1) AP2014007921A0 (fr)
AU (1) AU2013203619B2 (fr)
BR (1) BR112014021081A2 (fr)
CA (1) CA2865501A1 (fr)
CL (1) CL2014002258A1 (fr)
CO (1) CO7061039A2 (fr)
CR (1) CR20140451A (fr)
EA (1) EA201491599A1 (fr)
EC (1) ECSP14020644A (fr)
HK (4) HK1204981A1 (fr)
MD (1) MD20140108A2 (fr)
MX (2) MX2014010447A (fr)
MY (1) MY167236A (fr)
NZ (1) NZ629178A (fr)
PH (1) PH12014501927A1 (fr)
SG (2) SG10201610788VA (fr)
WO (1) WO2013130905A1 (fr)
ZA (1) ZA201406318B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027721A2 (fr) 2010-08-27 2012-03-01 Gilead Biologics, Inc Anticorps contre la métalloprotéinase de matrice 9
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
SG11201405305PA (en) 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
MD20140108A2 (ro) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
US10047141B2 (en) * 2014-01-30 2018-08-14 Coherus Biosciences, Inc. Method of manufacturing a protein by perfusion in media with a low amino acid concentration
CN106062001A (zh) * 2014-02-27 2016-10-26 吉利德科学公司 基质金属蛋白酶9的抗体及其使用方法
EP2985296A1 (fr) * 2014-08-13 2016-02-17 Calypso Biotech SA Anticorps spécifiques de MMP9
CA2957722C (fr) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anticorps anti-tigit
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
EP3355871A1 (fr) * 2015-10-02 2018-08-08 Gilead Sciences, Inc. Combinaisons de l'inhibiteur de btk gs-4059 avec des inhibiteurs choisis parmi un inhibiteur de jak, d'ask1, de brd et/ou de mmp9 pour traiter le cancer, les troubles allergiques, les maladies auto-immunes ou les maladies inflammatoires
WO2017106566A1 (fr) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combinaison d'un inhibiteur des jak et d'une protéine fixant mmp9 pour traiter des troubles inflammatoires
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
JP2019513737A (ja) * 2016-04-08 2019-05-30 ギリアード サイエンシーズ， インコーポレイテッド がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
TWI676482B (zh) * 2017-03-23 2019-11-11 高雄醫學大學 盤基蛋白結構域受體１的抑制劑及活化劑及其用途
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
KR102657653B1 (ko) 2017-07-18 2024-04-16 다이이찌 산쿄 가부시키가이샤 활성형 mmp-9 결합 펩티드
WO2019094608A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps anti-bace1 et leurs procédés d'utilisation
US12116415B2 (en) * 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
WO2020118293A2 (fr) * 2018-12-07 2020-06-11 Georgia Tech Research Corporation Anticorps qui se lient à la myociline pliée de manière native
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
WO2020237092A2 (fr) * 2019-05-21 2020-11-26 The Regents Of The University Of California Anticorps mmp-9 et leurs procédés d'utilisation
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
EP4076526A4 (fr) 2019-12-17 2024-07-03 The Board Of Regents Of The University Of Texas System Nouveaux anticorps ddr1 et leurs utilisations
US12649784B2 (en) 2020-03-30 2026-06-09 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
AU2023219174A1 (en) * 2022-02-09 2024-08-15 Sera Prognostics, Inc. Shbg and ibp4 antibodies and methods using same
CN114292834B (zh) * 2022-03-09 2022-05-31 天津辅元生物医药科技有限公司 一种融合蛋白酶及其制备方法、其在提取i型胶原蛋白中的应用以及该i型胶原蛋白的用途
CN122249232A (zh) * 2023-10-04 2026-06-19 宾夕法尼亚大学董事会 治疗、改善和/或预防进行性骨化性纤维发育不良和异位骨化的方法及其套组
CN117986368B (zh) * 2023-10-18 2024-11-29 深圳大学 抗肿瘤抗炎症相关的纳米抗体及其制备方法与应用
CN119060188B (zh) * 2024-08-30 2025-09-12 武汉爱博泰克生物科技有限公司 抗人基质金属蛋白酶9抗体、抗体对和检测试剂盒
CN119193495A (zh) * 2024-09-25 2024-12-27 广州通识生物医药有限公司 一种基因修饰的间充质干细胞的制备方法及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
DE69412466T2 (de) 1993-11-30 1999-04-29 Fuji Yakuhin Kogyo K.K., Takaoka, Toyama Neue metalloprotease und kodierende dna dafür
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
ES2327812T3 (es) 1999-07-13 2009-11-04 University Of Southern California Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
US7101975B1 (en) 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
AU2002235692A1 (en) 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv) 2001-06-27 2001-06-27 Astrazeneca Ab Crystal structure of enzyme and uses thereof
WO2003006006A1 (fr) 2001-07-09 2003-01-23 The Regents Of The University Of California Utilisation d'inhibiteurs de metalloproteinases matricielles pour limiter les atteintes nerveuses
AU2002352089A1 (en) 2001-11-23 2003-06-10 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
EP1545611B1 (fr) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Procede de traitement de l'asthme mettant en oeuvre des anticorps en complement du constituant c5
WO2004076614A2 (fr) 2003-02-27 2004-09-10 Bernd Hinzmann Sequences d'acide nucleique humaines issues de carcinomes de la prostate
ATE517926T1 (de) 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
JP4906094B2 (ja) * 2004-01-16 2012-03-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レセプターを活性化し得る融合ポリペプチド
WO2006037513A1 (fr) 2004-10-09 2006-04-13 Bayer Healthcare Ag Agents diagnostiques et agents therapeutiques utilises dans le cadre de maladies associees a la metalloproteinase 9 matricielle (mmp9)
WO2007094842A2 (fr) 2005-12-02 2007-08-23 Genentech, Inc. Polypeptides de liaison et leurs utilisations
EP1904846A4 (fr) 2005-06-29 2009-03-18 Rules Based Medicine Inc Méthodes et trousses pour le diagnostic du syndrome coronaire aigu
CN101370832B (zh) * 2005-12-02 2014-07-02 健泰科生物技术公司 结合多肽及其用途
WO2007144781A2 (fr) 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Procédés de diagnostic et trousses utilisant des anticorps dirigés contre des métalloprotéases
WO2008088864A2 (fr) 2007-01-18 2008-07-24 The Trustess Of Columbia University In The City Of New York Procédés associés à une métalloprotéinase-9 matricielle
EP2155691B1 (fr) 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Anticorps et compositions pharmaceutiques contenant ces anticorps utiles pour inhiber l'activité des métalloprotéines
PE20090765A1 (es) * 2007-06-08 2009-07-10 Irm Llc Metodos y composiciones para inducir la apoptosis en celulas cancerosas
CA2693310C (fr) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Inhibiteurs de lox et loxl2, anticorps et utilisations associees
BRPI0814479A2 (pt) 2007-08-15 2016-07-12 Yeda Res & Dev "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"
CA2707637A1 (fr) 2007-12-17 2009-06-25 Dyax Corp. Compositions et procedes pour traiter des troubles osteolytiques comprenant des proteines de liaison a mmp-14
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) * 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
WO2010048432A1 (fr) 2008-10-22 2010-04-29 Dyax Corp. Polythérapie comportant des protéines de liaison de protéase pour des troubles inflammatoires
WO2010059543A1 (fr) 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Génération et caractérisation d’anticorps anti-notch pour utilisation thérapeutique et diagnostique
DE102009030321A1 (de) * 2009-06-24 2011-01-05 Siemens Aktiengesellschaft Verfahren zur Abbildung von Tumorgewebe
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
US8896483B2 (en) * 2010-07-15 2014-11-25 Evgeny Markin Method of automatic target angle tracking by monopulse radar under conditions of interference distorting location characteristic
WO2012027721A2 (fr) 2010-08-27 2012-03-01 Gilead Biologics, Inc Anticorps contre la métalloprotéinase de matrice 9
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
SG11201405305PA (en) * 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
MD20140108A2 (ro) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale

Also Published As

Publication number Publication date
MY167236A (en) 2018-08-14
KR20140130513A (ko) 2014-11-10
BR112014021081A2 (pt) 2017-07-04
EP2819697A4 (fr) 2016-03-09
ECSP14020644A (es) 2015-09-30
EP2819697A1 (fr) 2015-01-07
EA201491599A1 (ru) 2015-05-29
US9732156B2 (en) 2017-08-15
EP3255063A3 (fr) 2018-02-07
HK1248246A1 (en) 2018-10-12
SG10201610788VA (en) 2017-03-30
US20130224210A1 (en) 2013-08-29
JP6343368B2 (ja) 2018-06-13
HK1204981A1 (en) 2015-12-11
CN107184974A (zh) 2017-09-22
MX2018007630A (es) 2023-04-12
MD20140108A2 (ro) 2015-03-31
US20180002446A1 (en) 2018-01-04
HK1204926A1 (en) 2015-12-11
CN104271156A (zh) 2015-01-07
EP3255063A2 (fr) 2017-12-13
WO2013130905A1 (fr) 2013-09-06
ZA201406318B (en) 2016-07-27
NZ629178A (en) 2016-09-30
JP2015509959A (ja) 2015-04-02
JP6144286B2 (ja) 2017-06-07
CL2014002258A1 (es) 2015-02-20
AP2014007921A0 (en) 2014-09-30
AU2013203619A1 (en) 2013-09-19
CA2865501A1 (fr) 2013-09-06
AU2013203619B2 (en) 2015-02-26
MX2014010447A (es) 2015-06-23
SG11201405273YA (en) 2014-09-26
CO7061039A2 (es) 2014-09-19
PH12014501927A1 (en) 2014-11-24
CN104271156B (zh) 2017-06-16
JP2017178952A (ja) 2017-10-05
JP2018150343A (ja) 2018-09-27
HK1244671A1 (zh) 2018-08-17

Similar Documents

Publication Publication Date Title
CR20140443A (es) Anticuerpos contra la metaloproteinasa de la matriz 9
ECSP14020644A (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
CR20130132A (es) Anticuerpos contra metalproteasa-9 de matriz
MX2022012089A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos.
CL2018003378A1 (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno.
CU20190109A7 (es) Moléculas de anticuerpo que se unen a cd73
MX2021007663A (es) Molecula de union al antigeno especifico para el tejido objetivo.
CL2015002756A1 (es) Moléculas fc biespecíficas
CY1119154T1 (el) Anti-vla-4 αντισωματα
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA201490454A1 (ru) Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
MX2021004686A (es) Anticuerpo anti-influenza a neutralizantes y usos de los mismos.
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
TH148296A (th) แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9)
PE20142189A1 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
CY1116623T1 (el) Συνθεσεις και μεθοδοι για αντισωματα κατα της πρωτεϊνης c5 συμπληρωματος